Skip to search formSkip to main contentSkip to account menu

AMD 473

Known as: AMD-473, AMD473 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
The effect of different N-N spectator ligands on the reactivity of platinum(II) complexes was investigated by studying the water… 
2006
2006
The preparation and oxidation of the anticancer drug AMD473, cis-[PtCl2(NH3)(2-pic)] (2-pic = 2-methylpyridine), has been… 
Highly Cited
2005
Highly Cited
2005
Platinum-based chemotherapeutic regimens are ultimately unsuccessful due to intrinsic or acquired drug resistance. Understanding… 
Highly Cited
2005
Highly Cited
2005
cis-[PtCl2(NH3)(2-picoline)] (AMD473) is currently on clinical trials as an anticancer drug. The trans isomer, AMD443 (1), is… 
2003
2003
AMD473 is a novel sterically hindered platinum cytotoxic with demonstrated ability to overcome acquired resistance to cisplatin… 
Highly Cited
1998
Highly Cited
1998
A novel sterically hindered platinum complex, AMD473 [cis-aminedichloro(2-methylpyridine) platinum (II)], has been selected for… 
Highly Cited
1998
Highly Cited
1998
cis-[Amminedichloro(2-methylpyridine)] platinum(II) (AMD473) is a novel sterically hindered anti-tumour compound designed to… 
Highly Cited
1997
Highly Cited
1997
A novel sterically hindered platinum complex, AMD473 [cis-amminedichloro(2-methylpyridine) platinum(II)], designed primarily to…